LTT Biopharma's IIP Agent PC-SOD Shows Promise In Phase II Trials
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based LTT Biopharma announced June 9 that its idiopathic interstitial pneumonia treatment, superoxide dismutase drug PC-SOD showed promise of becoming a therapeutic drug during Phase II trials. The company has decided to search for other pharmaceutical companies to jointly develop the drug and start Phase III trials. (Click here for more - Japanese language ) "LTT Shares Jump To Stop Price On PC-SOD's Possibility Of Being A Therapeutic Drug" - Reuters Japan (6/9/08)
You may also be interested in...
QUOTED. 5 August 2020. Eric Fanning.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Need a specific report? 1000+ reports available
Buy Reports